Gyre Therapeutics Inc. (GYRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $471.74M
Last updated: Nov 17, 2026 at 11:05 AM ET
Gyre Therapeutics Inc. (GYRE) Stock Forecast
Analysts expect Gyre Therapeutics (GYRE) to earn -$0.28 per share in the fiscal year ending Dec 31, 2026, on revenue of $112.63M. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 3 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 30.7%.
- Fiscal year ending Dec 31, 2026
- -$0.28
- EPS consensus, revenue $112.63M
- Fiscal year ending Dec 31, 2027
- -$0.20
- EPS consensus, revenue $147.20M
- Next report
- Mar 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.28 | -$0.34 to -$0.21 | 2 | $112.63M | $109.60M to $118.30M | 3 |
| Dec 31, 2027 | -$0.20 | -$0.38 to -$0.02 | 2 | $147.20M | $120.00M to $174.40M | 2 |
Quarterly Estimates
The EPS consensus falls from -$0.13 for the quarter ending Dec 31, 2026 to -$0.17 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.13 | -$0.20 to -$0.05 | 5 | $30.21M | $24.93M to $35.49M | 5 |
| Mar 31, 2027 | -$0.17 | -$0.17 to -$0.17 | 1 | $22.50M | $22.50M to $22.50M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.43.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.28 | -$0.40 | -$0.40 | -$0.40 | -$0.43 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.20 | -$0.24 | -$0.24 | -$0.24 | -$0.24 | N/A |
Frequently Asked Questions About GYRE
What is the GYRE stock forecast?
Consensus analyst estimates put Gyre Therapeutics's EPS at -$0.28 for the fiscal year ending Dec 31, 2026, on revenue of $112.63M. The consensus rating from 3 analysts is Buy.
How do analysts rate GYRE stock?
Of 3 analysts covering Gyre Therapeutics, 0 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from GYRE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.28, with estimates from -$0.34 to -$0.21 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.20, with estimates from -$0.38 to -$0.02 from 2 analysts.
What revenue do analysts expect from Gyre Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $112.63M, with estimates from $109.60M to $118.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $147.20M, with estimates from $120.00M to $174.40M.
How many analysts cover GYRE?
3 analysts rate Gyre Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
GYRE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors